Gutfast Capsule is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Pantoprazole 40 mg, designed for the effective management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, facilitates gastric motility and enhances gastric emptying, making it beneficial in treating conditions such as functional dyspepsia, gastroparesis, and gastroesophageal reflux disease (GERD) with associated motility disturbances. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, thereby providing symptomatic relief and promoting healing in acid-related disorders including erosive esophagitis and peptic ulcers. The synergistic action of these two agents addresses both the motor dysfunction and acid hypersecretion components of gastrointestinal pathologies, improving overall patient outcomes. Gutfast Capsule is indicated for patients presenting with symptoms such as epigastric pain, heartburn, bloating, and nausea related to delayed gastric emptying and acid reflux. It should be used under medical supervision, with caution advised in patients with known hypersensitivity to either component, and in those with pre-existing neurological or hepatic conditions. Common side effects may include headache, dizziness, and mild gastrointestinal disturbances. Regular monitoring and adherence to prescribed dosage are essential for optimal therapeutic efficacy.